Capital Fund Management (CFM)
BCRX icon

Capital Fund Management (CFM)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,200
Closed -$266K – 1449
2021
Q4 		$266K Buy
+19,200
New +$254K ﹤0.01% 1533

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital Fund Management (CFM)'s BCRX Position: Q1 2026 in Review

Capital Fund Management (CFM) opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 57,138 shares worth $544K. The stake represents ﹤0.01% of the portfolio and ranks #1857 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in BCRX as recently as Q2 2025.

Capital Fund Management (CFM) first reported a position in BCRX in Q2 2014 and has held it in 11 quarters since. The position peaked at $2.72M in Q3 2024. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Capital Fund Management (CFM) held 57,138 shares of BioCryst Pharmaceuticals worth $544K as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Capital Fund Management (CFM) position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1857 holding.
  • Capital Fund Management (CFM) first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
  • Capital Fund Management (CFM)'s BioCryst Pharmaceuticals position peaked at $2.72M in Q3 2024.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.